BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250515T190000
DTEND;TZID=Africa/Nairobi:20250515T203000
DTSTAMP:20260522T064558
CREATED:20250414T200633Z
LAST-MODIFIED:20250622T142308Z
UID:24390-1747335600-1747341000@kesho-kenya.org
SUMMARY:Bladder Cancer
DESCRIPTION:Moderator: Roselyne A. Okumu \nSpeakers & Topics: \n\nDr Melissa Reimers: Updates in the Management of Advanced Bladder Cancer\nProf Peter Mungai: Superficial Bladder Cancer Management\n\nManagement of Non-Muscle-Invasive Bladder Cancer (NMIBC) \n– NMIBC represents ~75% of new bladder cancer cases\, typically presenting with painless hematuria.\n– Diagnosis: Cystoscopy and TURBT; blue light cystoscopy improves detection.\n– Risk-based treatment approach:\n• Low/intermediate-risk: single post-op intravesical chemo (mitomycin C/gemcitabine)\n• High-risk: 6-week BCG induction ± maintenance\n– BCG-unresponsive NMIBC: radical cystectomy or emerging therapies.\n– Promising bladder-sparing agents: TAR-200 (gemcitabine) and TAR-210 (erdafitinib).\n– Trials (MoonRISe-3\, SunRISe-5) show >80% DFS in high-risk patients. \nUpdates in Advanced and Metastatic Bladder Cancer \n– Bladder cancer is the 4th most common male cancer globally.\n– Molecular profiling is critical: test for FGFR3 and HER2.\n– 1st-line standard: Enfortumab vedotin + Pembrolizumab (EV-302/KEYNOTE-A39).\n– Platinum-eligible: Cis/gem ± nivolumab; Carb/gem → Avelumab maintenance.\n– 2nd/3rd-line: Erdafitinib (FGFR+)\, T-DXd (HER2+).\n– Novel ADCs (Enfortumab\, Sacituzumab) offer superior outcomes to chemo.\n– Trial enrolment is encouraged for all patients. \nKey Clinical Takeaways \n– Intravesical innovation is changing NMIBC treatment beyond BCG.\n– Biomarker-driven therapy is now essential for managing advanced bladder cancer.\n– Routine molecular testing is critical for individualized care
URL:https://kesho-kenya.org/event/bladder-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Bladder-Cancer.jpg
END:VEVENT
END:VCALENDAR